International Isotopes posts results

Article

Radiopharmaceutical manufacturer International Isotopes last month posted its fiscal 1998 results (end-December). The Denton, TX, firm reported revenues of $2 million for the year, a dramatic increase over 1997’s $136,000. The company attributed the

Radiopharmaceutical manufacturer International Isotopes last month posted its fiscal 1998 results (end-December). The Denton, TX, firm reported revenues of $2 million for the year, a dramatic increase over 1997’s $136,000. The company attributed the increase to its International Isotopes Idaho subsidiary’s product sales, as well as income from development contracts. The company’s net loss for the year was $5.5 million, compared with the previous year’s $4.4 million loss.

In other news, the firm last month formed a joint venture with GammaPlus, an Austin, TX-based subsidiary of Lucas Medical Associates that operates short-lived radiopharmaceutical manufacturing centers. The joint venture will be called GammaPlus DFW, and will manufacture and distribute PET radiopharmaceuticals, including fluorodeoxyglucose F-18 (FDG). GammaPlus DFW will produce FDG with International Isotopes’ cyclotron, and expects to begin distributing the isotope within the next few months, according to Carl Seidel, president and CEO of International Isotopes. Distribution will be primarily to hospitals and clinics in the Dallas/Fort Worth area, Seidel said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
Current Insights on Interoperability, Enterprise Imaging and AI Integration in Radiology
A Closer Look at the Mammo Enhance Heart Program: An Interview with Arthy Saravanan, MD
Current Perspectives on Prostate Cancer and Emerging Theranostic Agents, Part 1
© 2025 MJH Life Sciences

All rights reserved.